Medlab Clinical (ASX: MDC)

Last close As at 18/11/2024

6.60

0.00 (0.00%)

Market capitalisation

AUD15m

Latest Insights

View More

Healthcare | Outlook

Medlab Clinical — NanaBis development centre stage in 2023

Healthcare | Flash note

Medlab Clinical — Encouraging real-world data to support NanaBis

Healthcare | Flash note

Medlab Clinical — Moving closer to the Nasdaq IPO

Healthcare | Flash note

Medlab Clinical — Progressing on multiple fronts

Test tube with DNA

Sector

Healthcare

Balance Sheet

Forecast net debt (A$m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 0.0 (5.7) (52.7)
Relative 4.4 (4.0) (49.9)
52 week high/low A$19.5/A$6.5

Financials

Edison Investment Research is terminating coverage on Medlab Clinical (MDC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (c) P/E (x) P/CF (x)
2021A 8.1 (11.4) (12.4) (627.0) N/A N/A
2022A 6.0 (7.4) (8.4) (314.0) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Further insights

insight

Healthcare

Healthcare Week 2023

insight

Healthcare

Medlab Clinical: A new focus on patient suffering

Thematics

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free